Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis
|
|
- Gwendoline Andrews
- 5 years ago
- Views:
Transcription
1 Original Article Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis Innate Immunity 19(6) ! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / ini.sagepub.com Jean-Pierre Gangneux 1,2, Yves Poinsignon 3, Ludovic Donaghy 2, Laurence Amiot 1,4, Karin Tarte 4,5, Charles Mary 6 and Florence Robert-Gangneux 1,2 Abstract Leishmania parasites induce an immunomodulation by subverting the host immune response towards a CD4 + Th2 lymphocytic cell response that favors parasite persistence. Here, we report that after successful treatment of visceral leishmaniasis due to Leishmania infantum, an immune reconstitution syndrome revealing hip septic arthritis was associated with a switch from Th2 towards a Th1 cytokine profile, and a decrease in the level of immunomodulating factors, such as soluble HLA-G and indoleamine 2,3-dioxygenase (IDO) activity. We then measured IDO activity in a cohort of 39 patients and uninfected control subjects. Results showed significantly enhanced IDO activity in patients with visceral Leishmania infection, compared with uninfected control subjects (P < 0.001), but also compared with treated patients (P < 0.05). A decrease in IDO activity could constitute a relevant biomarker for the restoration of the immune response during visceral leishmaniasis. Keywords Indoleamine 2,3-dioxygenase, immune reconstitution syndrome, visceral leishmaniasis, Leishmania, HLA-G, immune response Date received: 25 June 2012; revised: 13 October 2012; accepted: 20 November 2012 Introduction Visceral leishmaniasis (VL) is a severe parasitic infection due to Leishmania infantum in the mediterranean basin, notably as an opportunistic infection during AIDS. 1 In immunocompetent hosts, Leishmania parasites induce an immunomodulation by subverting the host immune response towards a CD4 + Th2 lymphocytic cell response that favors parasite persistence. After successful treatment, CD8 + T cell expansion combined with a switch from a Th2 to a Th1 response are the hallmarks of the resolution of immunosuppression. 1 Only a few cases of opportunistic infections during VL have been reported, i.e. tuberculosis and leprosy, which led to the debate of which infection underlined the other. 2 4 More recently, the concept of immune reconstitution syndrome (IRS) and its immunological mechanism has emerged. IRS is well known during the course of AIDS disease and solid organ transplantation (SOT), and was reported to be associated with various bacterial and viral infections, and also fungal and parasitic infections. 5,6 This syndrome has been described on the observation of unexplained severe concomitant infections, rising mainly in two situations: (i) after initiation of potent highly active antiretroviral therapy to treat HIV/AIDS and (ii) after reduction or 1 INSERM U 1085 IRSET (Institut de Recherche en Santé, Environnement et Travail), Université Rennes 1, France 2 Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, France 3 Service de Médecine Interne, Centre Hospitalier Bretagne Sud, Vannes, France 4 Département d Hémato-Immunologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Rennes, France 5 INSERM U917, Faculté de Médecine, Université Rennes 1, France 6 Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Marseille, Assistance Publique Hôpitaux de Marseille, France Corresponding author: Jean-Pierre Gangneux, Laboratoire de Parasitologie-Mycologie, Université Rennes 1, 2 rue du Pr Léon Bernard, Rennes cedex, France. jean-pierre.gangneux@univ-rennes1.fr
2 Gangneux et al. 565 withdrawal of immunosuppressive agents in SOT patients. In the literature, few cases of leishmaniasis that developed in the context of IRS were described, and all occurred in patients co-infected with HIV. 5,7 9 Here, we report, for the first time, that VL can also be an underlying disease predisposing to the development of IRS. We investigated the immunologic environment through dosages of serum biomarkers, including cytokines, soluble histocompatibility-leukocyte-antigen-g (shla-g) molecule and indoleamine 2,3-dioxygenase (IDO) activity. IDO has been reported recently as an immunoregulatory enzyme increased in lymph node in cutaneous Leishmania major infection. 10 In addition, we determined IDO activity in blood samples of a retrospective cohort of VL and control patients in order to analyze its interest as a biomarker of immune suppression and reconstitution during VL. Materials and methods Patients Case report of IRS after VL. A 75-year-old patient, living in France, presented with febrile hepatosplenomegaly and pancytopenia. The only noteworthy background consisted of right total hip arthroplasty for coxarthrosis 3 years ago. The patient also reported pain in the right hip appearing a few months prior to presentation, whilst holidaying in the South of France. VL is endemic in the south of France. A bone marrow aspiration was performed, which allowed the diagnosis of VL on a Giemsa-stained smear demonstrating intracellular amastigotes. The parasitic strain could be isolated by culture on Novy-McNeal-Nicolle medium and identified as L. infantum (Leishmania National Reference Center, University Montpellier 1). After treatment with liposomal amphotericin B at a dose regimen of 3 mg/kg at d 1, 2, 3, 4, 5 and 10, the patient presented with septic shock in relation to a systemic infection with a methicillin-sensitive Staphylococcus aureus, which was further proven to be related to a joint infection consecutive to the right total hip arthroplasty. Treatment included combined adapted anti-biotherapy and surgery. After 16 d of treatment with intravenous oxacillin and gentamycin, a negative culture of the abscess puncture was obtained. Treatment was switched to oral ofloxacin and rifampicin for 15 d and allowed a 1- stage revision of the acetabular cup without femoral stem changing. The total duration of anti-biotherapy was 3 months. A definitive cure of both VL and septic arthritis was confirmed after long-term followup of the patient, without relapse or sequelae. An immunological analysis was then performed in order to characterize this episode. Cohort of VL patients and control participants. Forty-three blood samples from 39 participants were obtained retrospectively from Marseille and Rennes teaching hospitals (Table 2). Blood samples from VL patients were collected at the time of their primary diagnosis (n ¼ 12 + IRS-VL patient) and during follow-up after treatment for four of them. Cases of HIV-VL co-infection were excluded from this study. The remaining 26 subjects were healthy blood donors. Local ethical committee approval was received for the study and informed consent of all participants was obtained. All samples were anonymized according to the French legislation for biomedical research and stored at 20 C until use. Cytokine assays IL-12, IL-10, IL-8 and IL-6 blood levels were measured in order to characterize the inflammatory and cytokinic environment of the IRS-VL patients. These tests were performed with the patients sera at the acute phase of VL and 3 months after anti-parasitic treatment by flow immunocytometry using the human inflammatory cytokine CBA kit Õ (Beckman Coulter, Villepinte, France). shla-g assay The level of shla-g was measured with a specific ELISA method validated at the Wet Workshop for Quantification of shla-g (2004; Essen, Germany). Results were calculated from a standard curve prepared with serial dilutions of HLA-G5 purified from LCL G5 cell-line culture supernatant and expressed in ng/ml as described previously. 10 This detection was performed with the IRS patient sera at the acute phase of VL and 3 months after anti-parasitic treatment. IDO activity assessment Systemic IDO activity was determined by measuring kynurenine and tryptophan levels (in mmol/l) by HPLC, using 3-nitro-L-tyrosine as an internal standard as described previously. 11 IDO activity represents the ratio of kynurenine:tryptophan. It was performed in plasma samples from 39 participants (1 IRS-VL patient, 12 VL patients and 26 control participants). Statistical analysis Data are expressed as mean SEM for each group of patients. Differences between groups were analyzed using non-parametric tests (Mann Whitney test). Statistical analysis was performed using GraphPad Prism 5.02 software. Differences were considered significant when the P-value was < 0.05, and graduated as *(P < 0.05), **(P < 0.01) and ***(P < 0.001).
3 566 Innate Immunity 19(6) Results Biomarkers of immune reconstitution after efficient treatment of the clinical case IL-12, IL-10, IL-8 and IL-6 levels were measured at the time of diagnosis and after treatment of the IRS-VL patient to characterize the cytokinic environment. During the acute phase of VL, the patient exhibited a high level of IL-10 (95 pg/ml) and IL-6 (92 pg/ml), and a low level of IL-12 (35 pg/ml; Table 1). After successful treatment with liposomal amphotericin B, IL-12 showed a twofold increase, whereas IL-10 and IL-6 decreased, suggesting a switch from a Th2 to a Th1 cytokinic environment. Unfortunately, IL-4 and IFNg could not be measured because of the limited volume of blood samples. Besides, IL-8 remained stable at a low level before and after treatment (38 and 33 pg/ml respectively). Regarding the level of shla-g, serum concentration level (85 and 89 ng/ml) during the initial Table 1. Cytokine blood levels in the patient with IRS-VL, determined by flow immunocytometry. At time of diagnosis (4 November 2003) IL pg/ml 80 pg/ml IL pg/ml 70 pg/ml IL-6 92 pg/ml 75 pg/ml IL-8 38 pg/ml 33 pg/ml After treatment (4 February 2004) phase was much higher than that usually observed during VL (a median shla-g concentration of 24 ng/ml was observed in a previous study) and similar to levels commonly observed during HIV infection. 10 We also observed that after efficient anti-parasitic treatment, shla-g levels progressively decreased in our patient to 20 ng/ml (plasma concentration in a control population 10 ) 3 months after the end of therapy (Figure 1). Finally, systemic IDO activity was enhanced at the initial phase of diagnosis (0.331) and dramatically decreased after treatment (0.067). Enhanced IDO activity during VL Systemic IDO activity was determined by measuring kynurenine and tryptophan in plasma samples of our patient and compared with samples obtained from 12 other VL patients at the time of diagnosis, 4 treated VL patients and 26 healthy participants. IDO activity was much higher in VL patients than in healthy participants ( vs , P < 0.001). When a follow-up after treatment was performed, IDO activity had decreased significantly in treated patients (P < 0.05), but remained, however, at significantly higher levels than healthy controls (P < 0.01) (Figure 2). Discussion We report here that the underlying background for IRS-related pyogenic infection is in our original clinical case the L. infantum infection itself, as investigations ruled out major causes of immunosuppression, i.e shla-g (ng/ml) November November January February 2004 Date of sampling Figure 1. shla-g levels determined by ELISA at different time points in the patient with IRS-VL. Decreasing titers were observed from onset of treatment (4 November 2003) to successful outcome (4 February 2004). Dotted line indicates baseline levels observed in healthy subjects.
4 Gangneux et al. 567 Table 2. Demographic and clinical characteristics of VL patients and healthy controls and results of plasmatic IDO activity (¼ ratio of kynurenine:tryptophan) (mean SEM). Patient Diagnosis Age (mean ¼ ) IDO activity at diagnosis 1 IRS-VL Primary VL Primary VL Primary VL Primary VL Primary VL Primary VL Primary VL Primary VL Primary VL Relapse VL Primary VL + HIV infection Primary VL + HBV infection Non-infected controls Mean HBV : hepatitis B virus IDO activity VL Treated VL Control Figure 2. IDO activity (¼ ratio of kynurenine:tryptophan) measured in the plasma of patients with visceral leishmaniasis before (VL; n ¼ 13) and after treatment (treated VL; n ¼ 4). Samples from healthy participants (n ¼ 26) were used as controls (*P < 0.05; **P < 0.01; ***P < 0.001). hematological malignancy, solid cancer, HIV infection, other common causes of infection and diabetes. This observation can be explained by the immunosuppressive character of the Leishmania infection itself. Treatment with liposomal amphotericin B resulted in the regression of clinical signs and the return to normal of white and red blood cell and platelet counts, as reported previously. 12 The resulting increase in phagocytic cell function efficiency was associated with a shift from a Th2 response towards a Th1 cell response. This immune reconstitution enabled an inflammatory response with biological and clinical signs to develop, in response to a previously silent pyogenic infection. An original approach in this work was to measure the level of shla-g and systemic IDO activity. HLA-G are non-classical class I MHC
5 568 Innate Immunity 19(6) molecules that have tolerogenic effects, such as inhibition of allogeneic T cell proliferation and natural killer cell-mediated cytolysis. 13,14 Materno-fetal tolerance, hematological malignancies and also infection with HIV are characterized by high shla-g levels. 13,14 We showed previously that patients display elevated levels of shla-g associated with a Th2 cytokine profile during VL. We therefore hypothesized that shla- G could contribute to the impairment of host resistance to Leishmania through suppression of NK cellmediated cytolysis and reduction of IFN-g production by T cells two mechanisms that are essential in the control of Leishmania infection. 10 Here, we observed that shla-g may also represent an immune biomarker of successful treatment. Besides, it was shown that IDO can induce tolerance and favor chronic infections through suppression of T cell proliferation resulting from either anergy or T-cell death mediated by tryptophane depletion and/or toxic metabolites. 14 Two recent studies showed that during experimental L. major and human Leishmania guyanensis cutaneous infections, IDO is overexpressed locally and subsequently attenuates the T cell stimulatory functions of dendritic cells and suppresses local T cell response, particularly the regulatory T cell response. 15,16 Here, we show, for the first time, that systemic IDO activity is detectable in the plasma of patients during visceral Leishmania infection and that the IDO pathway could also act as a molecular switch regulating host response. In a small number of patients, we also showed that after successful treatment, a decrease is observed, although it does not revert to the levels of healthy controls. This can be owing either to the average delay between diagnosis and time of sampling after treatment (a maximum of 3 months), but can also be a marker of asymptomatic carriage, even after clinical recovery. The limitation of our retrospective study is the small number of patients for which plasma was stored after treatment and thus available for dosage. However, these preliminary data encourage evaluation of the role of IDO in larger and prospective cohorts of patients, all the more so as, in a recent paper, Straten and Andersen proposed that IDO-specific T cells could, potentially, play a role in Leishmania vaccination in the near future. 17 Measurement of IDO activity and shla-g may thus constitute, together with Th1/Th2 cytokines levels, surrogate markers to indicate the resolution of VL, at least in immunocompetent patients. This point should be addressed in a prospective study aiming to characterize the kinetics of soluble biomarkers of the immune restoration after successful treatment compared to parasitological tools, such as direct examination, culture and anti-leishmania Abs. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest The authors do not have any potential conflicts of interest to declare. References 1. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: Chaudhuri A. Leishmaniasis masking tuberculosis. Lancet 1989; 2: Delobel P, Launois P, Djossou F, Sainte-Marie D and Pradinaud R. American cutaneous leishmaniasis, lepromatous leprosy, and pulmonary tuberculosis coinfection with downregulation of the T-helper 1 cell response. Clin Infect Dis 2003; 37: Montalban C and Calleja JL. Leishmaniasis masking tuberculosis. Lancet 1990; 335: Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV and Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. JInfectDis2005; 192: Singh N and Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, et al. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 2007; 157: Sinha S, Fernandez G, Kapila R, Lambert WC and Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 2008; 47: Tadesse A and Hurissa Z. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIVpositive patient after initiation of anti-retroviral therapy (ART). Ethiop Med J 2009; 47: Donaghy L, Gros F, Amiot L, Mary C, Maillard A, Guiguen C and Gangneux JP. Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. Clin Exp Immunol 2007; 147: Tattevin P, Monnier D, Tribut O, Dulong J, Bescher N, Mourcin F, et al. Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis 2010; 201: Sundar S, Reed SG, Sharma S, Mehrotra A and Murray HW. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 1997; 56: Lila N, Rouas-Freiss N, Dausset J, Carpentier A and Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 2001; 98: Mellor AL and Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: Bourreau E, Ronet C, Darcissac E, Lise MC, Sainte Marie D, Clity E, et al. Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun 2009; 77: Makala LH, Baban B, Lemos H, El-Awady AR, Chandler PR, Hou DY, et al. Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression. J Infect Dis 2011; 203: Straten PT and Andersen MH. A potential role of Indoleamine 2,3-Dioxygenase-Specific T cells in Leishmania vaccination. J Infect Dis 2011; 204:
New insights on leishmaniasis in immunosuppressive conditions
New insights on leishmaniasis in immunosuppressive conditions Javier Moreno Immunoparasitology Unit WHO Collaborative Center for Leishmaniasis Centro Nacional de Microbiología INSTITUTO DE SALUD CARLOS
More informationVisceral leishmaniasis: an endemic disease with global impact
Visceral leishmaniasis: an endemic disease with global impact Professor Olivier Lortholary, MD, PhD Department of Infectious and Tropical diseases Hôpital Necker-Enfants Malades Université Paris Descartes
More informationA Novel Noninvasive Method for Diagnosis of Visceral Leishmaniasis by. rk39 Test in Sputum Samples
JCM Accepts, published online ahead of print on 0 June 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationSynergistic effects of indoleamine 2,3-dioxygenase (IDO) inhibitor drugs and chemotherapy in melanoma.
Synergistic effects of indoleamine 2,3-dioxygenase (IDO) inhibitor drugs and chemotherapy in melanoma. Madhav D. Sharma Cancer Immunology, Inflammation, and Tolerance Program, Department of Pediatrics,
More informationKala-Azar- Treatment Update
JOURNAL OF ADVANCES IN MEDICINE (JAM) DOI: 10.5958/2319-4324.2016.00002.X REVIEW PAPER Kala-Azar- Treatment Update Anup Singh Associate Professor, Department of Medicine, Institute of Medical Sciences,
More informationLESSON 2: THE ADAPTIVE IMMUNITY
Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationPost Kala-azar Dermal Leishmaniasis (PKDL) from the field to the cellular and the subcellular levels
Post Kala-azar Dermal Leishmaniasis (PKDL) from the field to the cellular and the subcellular levels A M EL Hassan Institute of Endemic Diseases University of Khartoum Introduction PKDL is a VL related
More informationNOTES. Th1/Th2 Cytokine Profile in Patients Coinfected with HIV and Leishmania in Brazil
CLINICAL AND VACCINE IMMUNOLOGY, Oct. 2011, p. 1765 1769 Vol. 18, No. 10 1556-6811/11/$12.00 doi:10.1128/cvi.00076-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. NOTES Th1/Th2
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationEFFECT OF AN IMMUNOMODULATING DIET ON THE IMMUNE SYSTEM OF DOGS INFECTED WITH Leishmania infantum
EFFECT OF AN IMMUNOMODULATING DIET ON THE IMMUNE SYSTEM OF DOGS INFECTED WITH Leishmania infantum Summary The experiment conducted on the effects of the nutraceutical food Immuno Active on dogs suffering
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 04 Jan 2019 20:47:10 GMT) CTRI Number Last Modified On 25/04/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More information227 28, 2010 MIDTERM EXAMINATION KEY
Epidemiology 227 April 28, 2010 MIDTERM EXAMINATION KEY Select the best answer for the multiple choice questions. There are 64 questions and 9 pages on the examination. Each question will count one point.
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationImmunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters,
Immunology T-Lymphocytes 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters, karin.peters@rub.de The role of T-effector cells in the immune response against microbes cellular immunity humoral immunity
More informationCytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Cytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Understand the physiological
More informationEvaluation of rk28 antigen for serodiagnosis of visceral Leishmaniasis in India
ORIGINAL ARTICLE TROPICAL AND PARASITIC DISEASES Evaluation of rk8 antigen for serodiagnosis of visceral Leishmaniasis in India M. Vaish, A. Bhatia, S. G. Reed, J. Chakravarty and S. Sundar ) Department
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationAuthors Abongomera, C; Diro, E; Vogt, F; Tsoumanis, A; Mekonnen, Z; Admassu, H; Colebunders, R; Mohammed, R; Ritmeijer, K; van Griensven, J
MSF Field Research The Risk and Predictors of Visceral Leishmaniasis Relapse in HIV Co-infected Patients in Ethiopia: A Retrospective Cohort Study Authors Abongomera, C; Diro, E; Vogt, F; Tsoumanis, A;
More informationApplication for Inclusion of MILTEFOSINE on WHO Model List of Essential Medicines:
Application for Inclusion of MILTEFOSINE on WHO Model List of Essential Medicines: Comments re Feb 2011 reviews of the v 2010 application February 23, 2011 1. The application and its review In v 2010,
More informationGAFFI Fact Sheet. Disseminated histoplasmosis
F GAFFI Fact Sheet Disseminated histoplasmosis ION NS ACT ALOR ECTIO B O F F L G ND L IN FU NGA FU Disseminated histoplasmosis is a sub- acute infection that may be diagnosed in patients with impaired
More informationNew evidences. Biomarkers to explore immunoparalysis: what future for immunostimulation? B. François CHU Limoges (France)
New evidences Biomarkers to explore immunoparalysis: what future for immunostimulation? B. François CHU Limoges (France) Background Hotchkiss, NEJM 2003 New understanding of response in sepsis PICS Persistent
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationProf. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology
By Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology Lecture objectives: At the end of the lecture you should be able to: Enumerate features that characterize acquired immune response
More informationWhat is Kala-azar? What are Signs & Symptoms of Kala-Azar?
What is Kala-azar? Kala-azar is a slow progressing indigenous disease caused by a protozoan parasite of genus Leishmania In India Leishmania donovani is the only parasite causing this disease The parasite
More informationChapter 35 Active Reading Guide The Immune System
Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process
More informationQuestion 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell?
Abbas Chapter 2: Sarah Spriet February 8, 2015 Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? a. Dendritic cells b. Macrophages c. Monocytes
More informationImmunity. Acquired immunity differs from innate immunity in specificity & memory from 1 st exposure
Immunity (1) Non specific (innate) immunity (2) Specific (acquired) immunity Characters: (1) Non specific: does not need special recognition of the foreign cell. (2) Innate: does not need previous exposure.
More informationSingle-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study
MAJOR ARTICLE Single-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study S. Sundar, 1 T. K. Jha, 2 C. P. Thakur, 3 M. Mishra, 4 V. P. Singh, 1 and R.
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationImmune Reconstitution Following Hematopoietic Cell Transplant
Immune Reconstitution Following Hematopoietic Cell Transplant Patrick J. Kiel, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Indiana University Simon Cancer Center Conflicts of Interest Speaker Bureau
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationImmunological Aspects of Parasitic Diseases in Immunocompromised Individuals. Taniawati Supali. Department of Parasitology
Immunological Aspects of Parasitic Diseases in Immunocompromised Individuals Taniawati Supali Department of Parasitology 1 Defense mechanism in human Th17 (? ) Acute Chronic Th1 Th 2 Intracellular Treg
More information14/05/2013,, 50,,, 16 /4/2012, 2,. 38,5,.,.., (30py).,. ( t:36,7%, Hb:11,8g/dl), (PLT: ) (WBC:2400, lymph:700),, 2 /2012,. 1
,, 50,,, 16 /4/2012, 2,. 38,5,.,.., (30py).,. ( t:36,7%, Hb:11,8g/dl), (PLT:114.000) (WBC:2400, lymph:700),, 2 /2012,. 1 Ht 36.7 Hb 11.8 2.400 67/29 114 MCV 88 33 CRP 0.54 PCT 0.24 Fe 58 790 ng/ml INR
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationAdvances in Cancer Immunotherapy
Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationInternational Conference on Parasitology August 24-26, 2015 Philadelphia, Pennsylvania, USA
International Conference on Parasitology August 24-26, 2015 Philadelphia, Pennsylvania, USA SYMPOSIA THE CHALLENGE OF PARASITES AND IMMUNOSUPRESSION: FROM DIAGNOSIS TO TREATMENT from the bench to the bed
More informationOral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial
Tropical Medicine and International Health doi:10.1111/tmi.12015 volume 18 no 1 pp 96 100 january 2013 Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial Shyam Sundar 1,
More informationPathogens and the immune system
Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu Keck Hall 224 / 232-lab Lecture 8 BIOE 301-Bioengineering and World Health Review of lecture 7 Science Science is the human activity
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationImmunology and the middle ear Andrew Riordan
Immunology and the middle ear Andrew Riordan The Immune system is NOT there; To baffle medical students To keep Immunologists in a job To encourage experiments on mice The Immune system IS there as a defence
More informationThe Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationLeishmania and Human Immunodeficiency Virus Coinfection: the First 10 Years
CLINICAL MICROBIOLOGY REVIEWS, Apr. 1997, p. 298 319 Vol. 10, No. 2 0893-8512/97/$04.00 0 Copyright 1997, American Society for Microbiology Leishmania and Human Immunodeficiency Virus Coinfection: the
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationJPEMS Nantes, Basic Immunology Introduction to the immune system Definitions Structure and General Organization
JPEMS Nantes, 2014- Basic Immunology Introduction to the immune system Definitions Structure and General Organization Teacher: Pr. Régis Josien, Laboratoire Immunologie and INSERM U1064, CHU Nantes Regis.Josien@univ-nantes.fr
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationCLINICAL. Immune Restoration in the Context of HAART
CLINICAL Immune Restoration in the Context of HAART Des Martin, MB ChB, MMed, FCPath, DTM&H, DPH University of the Witwatersrand and SA HIV Clinicians Society The advent of highly active antiretroviral
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationLaboratory diagnosis of Blood and tissue flagellates
Laboratory diagnosis of Blood and tissue flagellates (Leishmania and trypanosma) Sarah Alharbi Clinical Laboratory department Collage of Applied Medical Sciences King Saud University Leishmania and trypanosma:
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationComparison of Clinical Features and Survival between Cryptococcosis in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Patients
Jpn. J. Infect. Dis., 61, 111-115, 2008 Original Article Comparison of Clinical Features and Survival between Cryptococcosis in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Patients Ubonvan
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationInstitut Pasteur du Cambodge scientific report and 2018 prospects Rapport 2017 et programmation scientifique 2018 IMMUNOLOGY PLATFORM
Institut Pasteur du Cambodge 2017 scientific report and 2018 prospects Rapport 2017 et programmation scientifique 2018 IMMUNOLOGY PLATFORM 3.4. IMMUNOLOGY PF (total 4 pages) 3.4.1. FUNCTIONAL STRUCTURE
More informationDNA vaccine, peripheral T-cell tolerance modulation 185
Subject Index Airway hyperresponsiveness (AHR) animal models 41 43 asthma inhibition 45 overview 41 mast cell modulation of T-cells 62 64 respiratory tolerance 40, 41 Tregs inhibition role 44 respiratory
More informationHelminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza
Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels
More informationManipulating the Tumor Environment
Manipulating the Tumor Environment Vincenzo Bronte Verona University Hospital vincenzo.bronte@univr.it Escape from immune control can be viewed as one of the «Hallmarks of Cancer» D. Hanahan and R. A.
More informationMicr-6005, Current Concepts of Immunology (Rutgers course number: 16:681:543) Spring 2009 Semester
Micr-6005, Current Concepts of Immunology (Rutgers course number: 16:681:543) (3 Credits) Spring 2009 Semester Course Director: (732-235-4501, ) Please note that this course is offered once every 2 years.
More informationThe Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
More informationAdaptive immunity. Adaptive Immunity. Principles of immune defense. Adaptive immunity. against extracellular or intracellular pathogens
Principles of immune defense Toxicology Course Vienna MODULE 12 Immunotoxicology, Allergy July 2, 2008 Prof. Erika Jensen-Jarolim, MD Dept. of Pathophysiology Medical University Vienna Gastrointestinaltrakt:
More informationHIV AND INFLAMMATION: A NEW THREAT
HIV AND INFLAMMATION: A NEW THREAT KAP ANNUAL SCIENTIFIC CONFERENC MAY 2013 DR JOSEPH ALUOCH FRCP,EBS Basic Components of the Immune System Immunology: cells and tissues involved in recognizing and attacking
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationThere are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell
There are 2 major lines of defense: Non-specific (Innate Immunity) and Specific (Adaptive Immunity) Photo of macrophage cell Development of the Immune System ery pl neu mφ nk CD8 + CTL CD4 + thy TH1 mye
More informationimmunity defenses invertebrates vertebrates chapter 48 Animal defenses --
defenses Animal defenses -- immunity chapter 48 invertebrates coelomocytes, amoebocytes, hemocytes sponges, cnidarians, etc. annelids basophilic amoebocytes, acidophilic granulocytes arthropod immune systems
More informationNonspecific External Barriers skin, mucous membranes
Immune system Chapter 36 BI 103 Plant-Animal A&P Levels of Defense Against Disease Nonspecific External Barriers skin, mucous membranes Physical barriers? Brainstorm with a partner If these barriers are
More informationShort-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment
MAJOR ARTICLE Short-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment Shyam Sundar, Neha Agrawal, Rakesh Arora, Dipti Agarwal, Madhukar Rai, and Jaya Chakravarty
More informationAdaptive Immune System
Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationModulating STAT Signaling to Promote Engraftment of Allogeneic Bone Marrow Transplant
Modulating STAT Signaling to Promote Engraftment of Allogeneic Bone Marrow Transplant Jacopo Mariotti, M.D. Center for Cancer Research, NCI, NIH Istituto Nazionale Tumori, Milano Verona; May 22, 2009 Non-myeloablative
More informationBases for Immunotherapy in Multiple Myeloma
Bases for Immunotherapy in Multiple Myeloma Paola Neri, MD, PhD Associate Professor of Medicine University of Calgary, Arnie Charbonneau Cancer Institute Disclosures Paola Neri MD, PhD Grants/research
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationIntermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Intermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption Joseph L. Yozviak DO,
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationCorso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA.
Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA Valentina Grosso The Inteferons 1957: Isaacs and Lindenmann discovered a
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationSupplementary Figure 1. Characterization of basophils after reconstitution of SCID mice
Supplementary figure legends Supplementary Figure 1. Characterization of after reconstitution of SCID mice with CD4 + CD62L + T cells. (A-C) SCID mice (n = 6 / group) were reconstituted with 2 x 1 6 CD4
More informationLeishmania/HIV co-infections in the second decade
Review Article Indian J Med Res 123, March 2006, pp 357-388 Leishmania/HIV co-infections in the second decade Israel Cruz, Javier Nieto, Javier Moreno, Carmen Cañavate, Philippe Desjeux* & Jorge Alvar**
More informationBlood Product Modifications: Leukofiltration, Irradiation and Washing
1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs
More informationCationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationNatural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri
Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human
More information